Symbols / BRTX $0.25 -12.40%
BRTX Chart
About
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. It also operates a commercial biocosmeceutical platform. In addition, the company provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 5.45M |
| Enterprise Value | -2.24M | Income | -12.67M | Sales | 383.40K |
| Book/sh | 0.28 | Cash/sh | 0.51 | Dividend Yield | — |
| Payout | 0.00% | Employees | 11 | IPO | — |
| P/E | — | Forward P/E | -0.22 | PEG | — |
| P/S | 14.21 | P/B | 0.92 | P/C | — |
| EV/EBITDA | 0.16 | EV/Sales | -5.83 | Quick Ratio | 1.31 |
| Current Ratio | 1.37 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.46 | EPS next Y | -1.17 | EPS Growth | — |
| Revenue Growth | -94.90% | Earnings | 2025-11-12 17:00 | ROA | -89.73% |
| ROE | -207.73% | ROIC | — | Gross Margin | 93.34% |
| Oper. Margin | -314.32% | Profit Margin | 0.00% | Shs Outstand | 21.61M |
| Shs Float | 8.34M | Short Float | 3.87% | Short Ratio | 0.05 |
| Short Interest | — | 52W High | 2.10 | 52W Low | 0.19 |
| Beta | 0.41 | Avg Volume | 9.07M | Volume | 1.47M |
| Target Price | $9.50 | Recom | None | Prev Close | $0.29 |
| Price | $0.25 | Change | -12.40% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.50
Mean price target
2. Current target
$0.25
Latest analyst target
3. DCF / Fair value
$-5.63
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.25
Low
$1.00
High
$18.00
Mean
$9.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-08-14 | main | Roth MKM | Buy → Buy | $18 |
| 2024-06-12 | main | Roth MKM | Buy → Buy | $15 |
| 2023-08-14 | reit | Roth MKM | Buy → Buy | $15 |
| 2022-12-07 | init | Roth Capital | — → Buy | $15 |
| 2022-09-28 | init | Maxim Group | — → Buy | $6 |
| 2021-12-01 | init | Roth Capital | — → Buy | $37 |
- BioRestorative eyes early back-pain stem cell use in four US states - Stock Titan Wed, 04 Mar 2026 08
- BioRestorative Therapies, Inc.'s (NASDAQ:BRTX) Profit Outlook - simplywall.st Wed, 05 Nov 2025 08
- BioRestorative Therapies stock falls after $1.1M registered offering - Investing.com Mon, 06 Oct 2025 07
- BioRestorative Therapies, Inc. to Participate in the - GlobeNewswire hu, 05 Mar 2026 13
- Market Movers | Winners: HCTI, ATPC, ANY | Losers: QVCGA, BRTX, IVDA - Trefis ue, 10 Feb 2026 08
- Breakeven On The Horizon For BioRestorative Therapies, Inc. (NASDAQ:BRTX) - Yahoo Finance ue, 15 Jul 2025 07
- Australia clears patent for cell therapy touted as GLP-1 alternative - Stock Titan ue, 24 Feb 2026 08
- BioRestorative Therapies, Inc. Reports Promising Phase 2 Clinical Trial Results for BRTX-100 at ISSCR 2025 Annual Meeting - Nasdaq Fri, 13 Jun 2025 07
- symbol__ Stock Quote Price and Forecast - CNN Mon, 05 Feb 2024 13
- BRTX Forecast — Price Prediction for 2026. Should I Buy BRTX? - Intellectia AI Sat, 31 May 2025 12
- 12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga Wed, 11 Feb 2026 08
- BioRestorative Announces Pricing of $5.0 Million Public Offering - GlobeNewswire Wed, 11 Feb 2026 08
- BioRestorative Therapies stock plunges after $5 million public offering - Investing.com hu, 12 Feb 2026 08
- Stem cell firm BioRestorative raises $5M for trials and R&D - Stock Titan Fri, 13 Feb 2026 08
- BioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance Wed, 12 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 11719 | 18750 | — | Stock Award(Grant) at price 1.60 per share. | SILVA FRANCISCO | Officer and Director | — | 2025-10-06 00:00:00 | D |
| 1 | 15625 | 25000 | — | Stock Award(Grant) at price 1.60 per share. | ALSTODT LANCE | Chief Executive Officer | — | 2025-10-06 00:00:00 | D |
| 2 | 1112 | 1757 | — | Sale at price 1.58 per share. | BROADRICK DALE | Beneficial Owner of more than 10% of a Class of Security | — | 2024-10-28 00:00:00 | D |
| 3 | 8308 | 10229 | — | Purchase at price 1.13 - 1.25 per share. | SILVA FRANCISCO | Officer and Director | — | 2024-04-09 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -13.18M | -18.97M | -24.27M | -26.22M |
| TotalUnusualItems | 1.81M | 4.00M | 5.52M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 1.81M | 4.00M | 5.52M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -8.98M | -10.42M | -13.22M | -44.30M |
| ReconciledDepreciation | 189.06K | 165.74K | 120.55K | 89.11K |
| ReconciledCostOfRevenue | 28.07K | 0.00 | ||
| EBITDA | -11.37M | -14.97M | -18.74M | -26.22M |
| EBIT | -11.56M | -15.14M | -18.86M | -26.31M |
| NetInterestIncome | 616.08K | 552.29K | 11.65K | -1.82M |
| InterestExpense | 1.82M | |||
| InterestIncome | 616.08K | 552.29K | 11.65K | |
| NormalizedIncome | -10.79M | -14.42M | -18.74M | -44.30M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -8.98M | -10.42M | -13.22M | -44.30M |
| TotalExpenses | 11.96M | 15.28M | 18.98M | 26.35M |
| TotalOperatingIncomeAsReported | -11.56M | -15.22M | -18.97M | -26.31M |
| DilutedAverageShares | 7.76M | 4.22M | 3.62M | 1.19M |
| BasicAverageShares | 7.76M | 4.22M | 3.62M | 1.19M |
| DilutedEPS | -1.16 | -2.47 | -3.65 | -37.30 |
| BasicEPS | -1.16 | -2.47 | -3.65 | -37.30 |
| DilutedNIAvailtoComStockholders | -8.98M | -10.42M | -13.22M | -44.30M |
| NetIncomeCommonStockholders | -8.98M | -10.42M | -13.22M | -44.30M |
| NetIncome | -8.98M | -10.42M | -13.22M | -44.30M |
| NetIncomeIncludingNoncontrollingInterests | -8.98M | -10.42M | -13.22M | -44.30M |
| NetIncomeContinuousOperations | -8.98M | -10.42M | -13.22M | -44.30M |
| PretaxIncome | -8.98M | -10.42M | -13.22M | -44.30M |
| OtherIncomeExpense | 1.96M | 4.17M | 5.63M | -16.18M |
| OtherNonOperatingIncomeExpenses | 150.85K | 169.66K | 107.09K | -16.18M |
| SpecialIncomeCharges | 0.00 | 250.00K | 0.00 | |
| OtherSpecialCharges | -250.00K | |||
| RestructuringAndMergernAcquisition | 0.00 | |||
| GainOnSaleOfSecurity | 1.81M | 4.00M | 5.27M | |
| NetNonOperatingInterestIncomeExpense | 616.08K | 552.29K | 11.65K | -1.82M |
| TotalOtherFinanceCost | -11.65K | 1.82M | ||
| InterestExpenseNonOperating | 1.82M | |||
| InterestIncomeNonOperating | 616.08K | 552.29K | 11.65K | |
| OperatingIncome | -11.56M | -15.14M | -18.86M | -26.31M |
| OperatingExpense | 11.93M | 15.28M | 18.98M | 26.35M |
| OtherOperatingExpenses | -83.33K | -110.52K | ||
| ResearchAndDevelopment | 5.35M | 4.03M | 3.51M | 729.06K |
| SellingGeneralAndAdministration | 6.58M | 11.33M | 15.58M | 25.62M |
| SellingAndMarketingExpense | 12.29K | |||
| GeneralAndAdministrativeExpense | 6.58M | 11.33M | 15.58M | 25.62M |
| OtherGandA | 6.58M | 11.33M | 15.58M | 25.62M |
| GrossProfit | 372.93K | 145.80K | ||
| CostOfRevenue | 28.07K | 0.00 | ||
| TotalRevenue | 401.00K | 145.80K | 119.80K | 46.00K |
| OperatingRevenue | 401.00K | 145.80K | 119.80K | 46.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| PreferredSharesNumber | 1.54M | 1.40M | 1.52M | |
| OrdinarySharesNumber | 6.92M | 4.71M | 3.68M | 3.52M |
| ShareIssued | 6.92M | 4.71M | 3.68M | 3.52M |
| TotalDebt | 0.00 | 162.32K | 301.64K | 670.70K |
| TangibleBookValue | 7.89M | 9.28M | 9.47M | 20.99M |
| InvestedCapital | 8.52M | 9.99M | 10.28M | 21.83M |
| WorkingCapital | 7.40M | 8.78M | 9.15M | 21.10M |
| NetTangibleAssets | 7.91M | 9.29M | 9.49M | 21.01M |
| CapitalLeaseObligations | 0.00 | 162.32K | 301.64K | 420.70K |
| CommonStockEquity | 8.52M | 9.99M | 10.28M | 21.58M |
| PreferredStockEquity | 13.98K | 13.98K | 15.18K | 15.43K |
| TotalCapitalization | 8.53M | 10.00M | 10.29M | 21.79M |
| TotalEquityGrossMinorityInterest | 8.53M | 10.00M | 10.29M | 21.60M |
| StockholdersEquity | 8.53M | 10.00M | 10.29M | 21.60M |
| RetainedEarnings | -155.68M | -146.70M | -136.28M | -134.15M |
| AdditionalPaidInCapital | 164.20M | 156.69M | 146.56M | 155.73M |
| CapitalStock | 14.67K | 14.45K | 15.55K | 15.79K |
| CommonStock | 692.00 | 471.00 | 369.00 | 353.00 |
| PreferredStock | 13.98K | 13.98K | 15.18K | 15.43K |
| TotalLiabilitiesNetMinorityInterest | 3.75M | 2.61M | 6.14M | 856.50K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 162.32K | 492.68K |
| LongTermDebtAndCapitalLeaseObligation | 162.32K | 492.68K | ||
| LongTermCapitalLeaseObligation | 0.00 | 162.32K | 301.64K | |
| LongTermDebt | 191.03K | |||
| CurrentLiabilities | 3.75M | 2.61M | 5.98M | 363.82K |
| OtherCurrentLiabilities | 2.52M | 1.54M | 5.54M | |
| CurrentDebtAndCapitalLeaseObligation | 162.32K | 139.33K | 178.03K | |
| CurrentCapitalLeaseObligation | 0.00 | 162.32K | 139.33K | 119.06K |
| CurrentDebt | 58.97K | |||
| OtherCurrentBorrowings | 58.97K | |||
| PayablesAndAccruedExpenses | 1.23M | 901.08K | 300.97K | 185.80K |
| CurrentAccruedExpenses | 744.49K | 711.69K | 130.07K | 134.97K |
| Payables | 483.07K | 189.39K | 170.90K | 50.83K |
| AccountsPayable | 483.07K | 189.39K | 170.90K | 50.83K |
| TotalAssets | 12.28M | 12.61M | 16.43M | 22.45M |
| TotalNonCurrentAssets | 1.14M | 1.22M | 1.31M | 985.54K |
| NonCurrentDeferredAssets | 148.70K | 0.00 | ||
| GoodwillAndOtherIntangibleAssets | 623.95K | 713.69K | 803.44K | 589.74K |
| OtherIntangibleAssets | 623.95K | 713.69K | 803.44K | 589.74K |
| NetPPE | 362.94K | 507.50K | 502.76K | 395.80K |
| AccumulatedDepreciation | -1.11M | -1.01M | -935.84K | -893.63K |
| GrossPPE | 1.47M | 1.52M | 1.44M | 1.29M |
| Leases | 342.05K | 342.05K | 342.05K | 304.66K |
| OtherProperties | 853.55K | 898.81K | 594.99K | 740.65K |
| MachineryFurnitureEquipment | 278.47K | 278.47K | 259.81K | 244.11K |
| BuildingsAndImprovements | 151.45K | 241.76K | ||
| CurrentAssets | 11.14M | 11.39M | 15.13M | 21.47M |
| OtherCurrentAssets | 223.23K | 305.23K | 363.08K | 436.18K |
| PrepaidAssets | 436.18K | |||
| Receivables | 188.40K | 19.30K | 16.00K | 5.00K |
| AccountsReceivable | 188.40K | 19.30K | 16.00K | 5.00K |
| CashCashEquivalentsAndShortTermInvestments | 10.73M | 11.07M | 14.75M | 21.03M |
| OtherShortTermInvestments | 10.18M | 10.18M | 13.04M | 0.00 |
| CashAndCashEquivalents | 547.89K | 884.38K | 1.71M | 21.03M |
| CashFinancial | 21.03M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -8.34M | -6.60M | -6.35M | -3.36M |
| IssuanceOfDebt | 0.00 | 250.00K | ||
| IssuanceOfCapitalStock | 0.00 | 2.35M | 0.00 | 21.07M |
| CapitalExpenditure | -106.19K | -171.04K | -440.22K | -30.66K |
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 547.89K | 884.38K | 1.71M | 21.03M |
| BeginningCashPosition | 884.38K | 1.71M | 21.03M | 3.06M |
| ChangesInCash | -336.49K | -829.39K | -19.31M | 17.96M |
| FinancingCashFlow | 7.38M | 2.35M | 0.00 | 21.32M |
| CashFlowFromContinuingFinancingActivities | 7.38M | 2.35M | 0.00 | 21.32M |
| NetOtherFinancingCharges | -148.70K | |||
| ProceedsFromStockOptionExercised | 7.53M | 0.00 | ||
| NetCommonStockIssuance | 0.00 | 2.35M | 0.00 | 21.07M |
| CommonStockIssuance | 0.00 | 2.35M | 0.00 | 21.07M |
| NetIssuancePaymentsOfDebt | 0.00 | 250.00K | ||
| NetLongTermDebtIssuance | 0.00 | 250.00K | ||
| LongTermDebtIssuance | 0.00 | 250.00K | ||
| InvestingCashFlow | 514.53K | 3.25M | -13.40M | -30.66K |
| CashFlowFromContinuingInvestingActivities | 514.53K | 3.25M | -13.40M | -30.66K |
| NetInvestmentPurchaseAndSale | 620.72K | 3.42M | -12.96M | 0.00 |
| SaleOfInvestment | 21.51M | 20.96M | 9.49M | |
| PurchaseOfInvestment | -20.89M | -17.54M | -22.45M | 0.00 |
| NetIntangiblesPurchaseAndSale | 0.00 | -175.00K | 0.00 | |
| PurchaseOfIntangibles | 0.00 | -175.00K | 0.00 | |
| NetPPEPurchaseAndSale | -106.19K | -171.04K | -265.22K | -30.66K |
| PurchaseOfPPE | -106.19K | -171.04K | -265.22K | -30.66K |
| OperatingCashFlow | -8.23M | -6.43M | -5.91M | -3.33M |
| CashFlowFromContinuingOperatingActivities | -8.23M | -6.43M | -5.91M | -3.33M |
| ChangeInWorkingCapital | 28.65K | 515.33K | 14.14K | 324.69K |
| ChangeInOtherCurrentLiabilities | -162.32K | -139.33K | -163.13K | -101.19K |
| ChangeInPayablesAndAccruedExpense | 326.48K | 600.10K | 115.18K | 744.65K |
| ChangeInAccruedExpense | 32.80K | 581.62K | -4.90K | 812.67K |
| ChangeInInterestPayable | 812.67K | |||
| ChangeInPayable | 293.68K | 18.49K | 120.08K | -68.02K |
| ChangeInAccountPayable | 293.68K | 18.49K | 120.08K | -68.02K |
| ChangeInPrepaidAssets | 33.59K | 57.85K | 73.10K | -330.77K |
| ChangeInReceivables | -169.10K | -3.30K | -11.00K | 12.00K |
| ChangesInAccountReceivables | -169.10K | -3.30K | -11.00K | 12.00K |
| OtherNonCashItems | 151.45K | 90.31K | -89.88K | 1.27M |
| StockBasedCompensation | 2.81M | 7.78M | 12.61M | 23.11M |
| UnrealizedGainLossOnInvestmentSecurities | -33.66K | 0.00 | ||
| DepreciationAmortizationDepletion | 189.06K | 165.74K | 120.55K | 89.11K |
| DepreciationAndAmortization | 189.06K | 165.74K | 120.55K | 89.11K |
| AmortizationCashFlow | 89.75K | 89.75K | 78.33K | |
| AmortizationOfIntangibles | 89.75K | 89.75K | 78.33K | |
| Depreciation | 99.31K | 75.99K | 42.21K | |
| OperatingGainsLosses | -2.43M | -4.57M | -5.35M | 16.18M |
| GainLossOnInvestmentSecurities | -2.43M | -4.57M | -5.35M | |
| NetIncomeFromContinuingOperations | -8.98M | -10.42M | -13.22M | -44.30M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BRTX
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|